Evidence map›Paper›PMID 24794429›Full record

ArticleCell reports2014

Patterns of somatically acquired amplifications and deletions in apparently normal tissues of ovarian cancer patients.

Leila Aghili, Jasmine Foo, James DeGregori, Subhajyoti De

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Leila AghiliDepartment of Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Jasmine FooSchool of Mathematics, University of Minnesota, Minneapolis, MN 55455, USA.
James DeGregoriDepartment of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, CO 80045, USA; Molecular Oncology Program, University of Colorado Cancer Center, Aurora, CO 80045, USA.
Subhajyoti DeDepartment of Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA; Molecular Oncology Program, University of Colorado Cancer Center, Aurora, CO 80045, USA; Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO 80045, USA. Electronic address: subhajyoti.de@ucdenver.edu.
Molecular Oncology (United States) · USUniversity of Colorado Cancer Center · USUniversity of Colorado Denver · USUniversity of Minnesota · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Aging-associated alterations in adaptive landscapes and the evolution of leukemiaR01CA180175 · NCI · UNIVERSITY OF COLORADO DENVER · PI DEGREGORI, JAMES V · 2013 to 2018
$1.8M
Rationally designed targeted therapeutic approaches for NSCLCR01CA157850 · NCI · UNIVERSITY OF COLORADO DENVER · PI DEGREGORI, JAMES V · 2011 to 2015
$1.5M
NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA157850NCI NIH HHS R01 CA180175NCI NIH HHS R01CA180175
6 · The paper itself

Abstract

Little is understood about the occurrence of somatic genomic alterations in normal tissues and their significance in the context of disease. Here, we identified potential somatic copy number alterations (pSCNAs) in apparently normal ovarian tissue and peripheral blood of 423 ovarian cancer patients. There were, on average, two to four pSCNAs per sample detectable at a tissue-level resolution, although some individuals had orders of magnitude more. Accordingly, we estimated the lower bound of the rate of pSCNAs per cell division. Older individuals and BRCA mutation carriers had more pSCNAs than others. pSCNAs significantly overlapped with Alu and G-quadruplexes, and the affected genes were enriched for signaling and regulation. Some of the amplification/deletion hotspots in pan-cancer genomes were hot spots of pSCNAs in normal tissues as well, suggesting that those regions might be inherently unstable. Prevalence of pSCNA in peripheral blood predicted survival, implying that mutations in normal tissues might have consequences for cancer patients.

Indexed as

Case-Control StudiesDNA Copy Number VariationsFemaleGene AmplificationGene DeletionGene DosageGenomicsHumansLung NeoplasmsMutationOvarian NeoplasmsSequence Deletion

Identifiers

PMID24794429
PMCPMC4108616
OpenAlexW2004224646

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.